CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Asgard Therapeutics is developing a groundbreaking gene therapy called TrojanDC, which aims to transform cancer treatment. By reprogramming cancer cells into immune cells, this therapy seeks to enhance the body’s immune response against tumors, potentially offering a more effective and personalized approach to cancer i…
Asgard Therapeutics, a Swedish start-up company, was founded based on a unique proprietary in vivo cell reprogramming technology.
This paradigm-shifting gene therapy has the unique potential to overhaul the cancer immunotherapy market.Our gene therapy, named TrojanDC, delivers immune-genes into the tumor and re-educates cancer cells to become anti-tumor immune cells.
It uses a viral vector to deliver a unique combination of three critical transcription factors (genes) through intra-tumoral injec…
ASGARD THERAPEUTICS AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
